Wegovy Weight Loss

Wegovy (semaglutide 2.4 mg), the first and only once-weekly GLP-1 therapy for weight management

wegovy weight loss approved by FDA based on phase 3 data which showed that Wegovy helped 33% of patients lose. Also more than 20% of their body weight over a 68-week clinical trial period. More so the high-dose version of semaglutide is a first of its kind obesity. This medication in that it is dosed on a once-weekly basis

Researchers found that people who took Wegovy lost an average of 17% to 18% of their body weight. As compared to those who didn’t receive the drug. In trials conducted on those with diabetes, Wegovy helped people lose a more modest 6.2% of their body weight

HOW DOES WEGOVY WEIGHT LOSS WORK

How does it work for weight loss? GLP-1 is an incretin hormone that plays a role in your appetite and digestion. Incretins — hormones released by your small intestine — are sent out by your body after you’ve eaten a meal to help lower your blood sugar by triggering insulin and blocking other sources of sugar

The approval of Wegovy in the U.S. brings great promise to people with obesity. Despite the best efforts to lose weight, many people with obesity struggle to achieve and maintain weight loss due to physiological responses that favor weight regain,” “The unprecedented weight loss for an anti-obesity medication marks a new era in the treatment of obesity, and we now look forward to making Wegovy available to people living with obesity in the US